Role of Stent Grafts and Helical-Woven Bare-Metal Stents in the Superficial Femoral and Popliteal Arteries

2016 ◽  
Vol 19 (2) ◽  
pp. 153-162 ◽  
Author(s):  
Sreekumar Madassery ◽  
Ulku C. Turba ◽  
Bulent Arslan
Vascular ◽  
2021 ◽  
pp. 170853812110232
Author(s):  
Peixian Gao ◽  
Changliang Li ◽  
Xuejun Wu ◽  
Gang Li ◽  
Dianning Dong ◽  
...  

Purpose To evaluate the safety and efficacy of transbrachial and transfemoral approaches combined with visceral protection for the endovascular treatment of juxtarenal aortoiliac occlusive disease (AIOD) over an average 19-month follow-up period. Methods In this retrospective analysis, all patients with juxtarenal AIOD at a single institution were reviewed from June 2015 to January 2020. Patient characteristics, angiographic results, and follow-up outcomes were retrospectively recorded. The indications for treatment were critical limb threatening ischemia in 12 patients and bilateral claudication in five patients. Percutaneous access via the left brachial artery was first obtained to recanalize the infrarenal occluded lesions. After that, femoral accesses were achieved. A 4-Fr catheter, a 4 mm balloon, or a 6-Fr 90-cm-long sheath was used to complete visceral artery protection. Results A total of 17 juxtarenal AIOD patients (14 males; mean age, 63.4 ± 8.1 years) underwent endovascular treatment. The technical success rate was 100%. Complete reconstruction was achieved in 15 (88.2%) patients. The infrarenal aorta was reconstructed with kissing covered stent grafts ( n = 7), kissing bare-metal stents ( n = 2), covered stent grafts ( n = 2), bare-metal stents ( n = 1), or the off-label use of iliac limb stent grafts ( n = 5). Renal embolization was found in 3 (17.6%) patients during intraoperative angiography. There was 1 (5.9%) case of distal runoff embolization after CDT and 1 (5.9%) case of left iliac artery rupture. One (5.9%) death occurred due to acute myocardial infarction 20 days after the operation. The average follow-up period was 19.3 ± 16.7 months (range, 1–54 months) in the remaining 16 cases. The renal artery patency rate was 100%. The estimated cumulative primary patency rates were 92.3% at 12 months and 59.3% at 36 months according to the Kaplan–Meier method. Conclusions Transbrachial and transfemoral approaches combined with visceral protection offer a safe and effective alternative to open revascularization for the endovascular treatment of juxtarenal AIOD.


Author(s):  
Susheil Uthamaraj ◽  
Brandon J. Tefft ◽  
Soumen Jana ◽  
Ota Hlinomaz ◽  
Manju Kalra ◽  
...  

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Aleksei Zulkarnaev ◽  
Vadim Stepanov ◽  
Ekaterina Parshina ◽  
Mariya Novoseltseva

Abstract Background and Aims According to the current KDIGO guidelines, angioplasty should be preferred procedure for treatment of CVS instead of the bare metal stents or self-expanding stent-grafts placement. However, bare stents are still significantly more affordable than stent grafts. Aim: comparative analysis of the results of isolated balloon angioplasty (BA) and combined technique (BA with a stent placement in HD patients with central vein stenosis (CVS). Method A retrospective study included 62 patients with functional AVF and confirmed CVS: subclavian, brachiocephalic veins, vena cava inferior, or multiple lesions. In 39 patients, stents were not used; isolated balloon angioplasty (BA) was performed. In 23 patients we used bare metal stents during the first endovascular treatment. Results The use of stents leads to increase of primary patency (the time interval between the first and second endovascular interventions) – fig. 1A; HR (BA only vs. stenting) 2.064 [95% CI 1.252; 3.404], p = 0.0017. The use of stents allows to increase secondary patency (the time interval between the first endovascular intervention and the complete cessation of the use of AVF): HR=2.03 [95% CI 1.232; 3.347], p = 0.0021; fig 1B. Total need for surgical interventions did not differ: BA only 1.511 [95% CI 1.225; 1.843] and BA+stenting 1.277 [95% CI 0.997; 1.611] per 10 patient-months, incidence rate ratio 1.183 [95% CI 0.872; 1.612] p=0.2822. The second isolated BA allowed to increase patency compared to the first (HR of AVF function loss or relapse 0.512 [95% CI 0.32; 0.818], log rank p=0.001), and the third compared to the second isolated BA (HR=0.607 [95% CI 0.384; 0.959], log rank p=0.0157). The fourth isolated BA also showed a slight increase in AVF patency, but in this case we observed no significant difference with the previous intervention (HR= 0.783 [95% CI 0.501; 1.225], log rank p=0.2433). In the case of BA+stenting, the second intervention, which was consisted of stent recanalization, allowed to increase patency of the AVF (HR= 0.433 [95% CI 0.231; 0.813], log rank p= 0.0014), but the third intervention was no longer accompanied by a significant increase in patency (HR= 0.873 [95% CI 0.489; 1.558], log rank p= 0.629) and AVF function was completely lost. Conclusion The use of stents leads to a moderate increase in the median patency of AVF and a significant increase in the proportion of patients with functional AVF in the long-term period. However, repeated surgeries are significantly less effective than in a case of isolated BA. Therefore, we consider isolated BA to be the optimal treatment strategy, and stenting should be used only if the isolated BA does not result in clinical improvement. Multiple endovascular interventions can extend the duration of AVF functioning, however, in our study, AVF function was completely lost up to 52 months after the clinical manifestation of CVS in all patients. Thus, isolated BA and BA combined with a bare metal stent placement cannot be considered as a definitive treatment of CVS. Endovascular interventions provide only the necessary amount of time to create vascular access on the contralateral side or for shift of modality of renal replacement therapy.


2019 ◽  
Vol 21 (4) ◽  
pp. 504-510 ◽  
Author(s):  
TY Tang ◽  
CS Tan ◽  
CJQ Yap ◽  
RY Tan ◽  
HH Tay ◽  
...  

Background: The treatment options for cephalic arch stenosis are limited and standard of care remains at crossroads – none are ideal and there is currently no gold standard. Endovascular techniques are now the preferred primary therapeutic option because they are minimally invasive and better tolerated by haemodialysis patients who have multiple comorbidities. However, conventional plain old balloon angioplasty, bare metal stenting and stent grafts all have their limitations. The aim of this trial is to evaluate whether the helical SUPERA™ stent (Abbott Vascular, Santa Clara, CA, USA), which has a higher degree of flexibility and resistance to compressive forces compared to traditionally laser-cut nitinol stents, combined with a drug-coated balloon (Biotronik Passeo-18 Lux™) to minimize the neointimal hyperplasia effect, can improve patency and reduce reintervention rates. Methods and results: Arch V SUPERA-LUX is a pilot investigator-initiated single-centre, single-arm prospective study. Twenty patients with a brachiocephalic fistula within 6 months of initial plain old balloon angioplasty for significant cephalic arch stenosis will be recruited for treatment with SUPERA and drug-coated balloon. The primary objectives are immediate angiographic and procedural success, primary patency and functional fistula at 1 week, 8 weeks, 6 and 12 months. The results from eight patients treated prospectively as proof of concept have shown primary patency of 83.3% at 1 year with 100% technical and procedural success rates. Enrolment for the Arch V SUPERA-LUX study is expected to be completed at the end of 2019. Conclusion: The Arch V SUPERA-LUX study is the first trial to evaluate whether SUPERA stent implantation and drug-coated balloon use can provide superior protection against restenosis compared to traditional angioplasty, bare metal stents and stent grafts in recurrent cephalic arch stenosis. Initial pilot results are encouraging but longer follow-up is required to truly test this technique. Trial registration: This study is registered on ClinicalTrials.gov NCT03891693.


2012 ◽  
Vol 26 (2) ◽  
pp. 389-395 ◽  
Author(s):  
Dimitris Karnabatidis ◽  
Panagiotis Kitrou ◽  
Stavros Spiliopoulos ◽  
Konstantinos Katsanos ◽  
Athanasios Diamantopoulos ◽  
...  

2011 ◽  
Vol 79 (3) ◽  
pp. 496-496
Author(s):  
Juan Mieres ◽  
Carlos Fernandez-Pereira ◽  
A. Matias Rodriguez-Granillo ◽  
Alfredo E Rodriguez

Sign in / Sign up

Export Citation Format

Share Document